Australia markets closed

INVO Bioscience, Inc. (INVO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4601+0.0451 (+10.87%)
At close: 04:00PM EST
0.4602 +0.00 (+0.02%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.4150
Open0.4676
Bid0.0000 x 2200
Ask0.0000 x 1200
Day's range0.4101 - 0.4690
52-week range0.3290 - 4.0590
Volume111,179
Avg. volume29,196
Market cap5.598M
Beta (5Y monthly)0.11
PE ratio (TTM)N/A
EPS (TTM)-0.6260
Earnings date14 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.00
  • PR Newswire

    First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

    INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the birth of the first baby in Malaysia utilizing the INVOcell solution. The healthy baby boy weighed 3.53 kg and was born on November 11, 2022 at Tuanku Mizan Military Hospital in Kuala Lumpur. Physicians at Advanced Reproductive Centre (ARC), at Hospita

  • PR Newswire

    INVO Bioscience Reports Third Quarter 2022 Financial Results

    INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

  • PR Newswire

    INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

    INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its third quarter 2022, ended September 30, 2022, after the market close on Monday, November 14, 2022. The Company has scheduled a conference call that same day, Monday, November 14, 2022, at 4:30 pm ET, to review the results.